The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×

Objective:

This study aimed to describe state Medicaid psychotropic-monitoring programs targeting youths.

Methods:

Key informants from each state Medicaid administration and the District of Columbia were invited to participate in a telephone-administered survey designed to assess the implementation strategies of the state psychotropic-monitoring program. Data were collected from August 2011 through December 2012. A total of 38 states participated, four declined, and nine did not respond to the invitation. Descriptive statistics were used to characterize monitoring programs.

Results:

Key informants from 28 of the 38 states (74%) reported a program in place, mostly prior authorization (68%). One-third of the programs (32%) had a two-tier review involving pharmacists and child psychiatrists.

Conclusions:

Although variability in psychotropic-monitoring programs may limit comparison of program impact across states, the variability provides an opportunity to investigate the impact of different models on best practices and the quality of care.